10:14 AM EST, 12/19/2024 (MT Newswires) -- Personalis ( PSNL ) was surging early in Thursday's regular trading session, climbing almost 26%, after the cancer genomic testing and analytics company disclosed a $50 million investment from Merck ( MRK ) and a multiyear extension agreement with Moderna ( MRNA ) .

Merck ( MRK ) will buy around 14 million Personalis ( PSNL ) shares at $3.56 apiece, matching Wednesday's closing price and providing Merck ( MRK ) with roughly 16.5% of the company's outstanding stock, Personalis ( PSNL ) said.

Personalis ( PSNL ) said it also extended its collaboration with Moderna ( MRNA ) to use the company's ImmunoID NeXT tumor-profiling platform to assist with the testing of V940/mRNA-4157 individualized neoantigen therapy being developed jointly by Moderna ( MRNA ) and Merck ( MRK ). Financial details of the extended agreement weren't provided.

Price: 4.47, Change: +0.91, Percent Change: +25.56